Prevalence of Psoriatic Arthritis in Patients with Moderate-to-Severe Psoriasis in the Era of Biologics and Small Molecule Therapies.

Simple item page
dc.contributor.authorVergara Dangond, Cristina
dc.contributor.authorRichi Alberti, Patricia
dc.contributor.authorCobo Ibáñez, María Tatiana
dc.contributor.authorValverde Garrido, Ricardo
dc.contributor.authorGarcía Yubero, Cristina
dc.contributor.authorTrives Folguera, Laura
dc.contributor.authorParedes Romero, María Beatriz
dc.contributor.authorEsteban Vázquez, Ana
dc.contributor.authorRomero Bogado, Liz
dc.contributor.authorCámara Fernández, Isabel de la
dc.contributor.authorSteiner, Martina
dc.contributor.authorPrats, Iolanda
dc.contributor.authorMuñoz Fernández, Santiago
dc.contributor.authorEt. al.
dc.date.accessioned2026-02-18T11:46:40Z
dc.date.available2026-02-18T11:46:40Z
dc.date.issued2025
dc.description.abstractThis study aims to estimate the prevalence of psoriatic arthritis (PsA) and associated factors in patients with moderate-to-severe psoriasis. The study develops a retrospective, single-center study of a cohort of psoriasis patients in standard follow-up in a dermatology department from July 2008 to January 2024. Patients ≥18 years with moderate-to-severe psoriasis were included and classified into three groups according to the treatment received: group 1, biologics or small molecules with or without conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs); group 2, only csDMARDS; and group 3, non-pharmacological treatments. Demographic and clinical variables were collected.en
dc.description.filiationUEMspa
dc.description.impact2.9 Q1 JCR 2024
dc.description.impact0.919 Q1 SJR 2024
dc.description.impactNo data IDR 2024
dc.description.sponsorshipThe APC was funded by FIIB HUIS-HUEN.en
dc.identifier.citationVergara-Dangond, C., Cobo-Ibáñez, T., Cueva-Nájera, G., Valverde-Garrido, R., García-Yubero, C., Trives-Folguera, L., Paredes-Romero, B., Esteban-Vázquez, A. V., Romero-Bogado, L., De La Cámara-Fernández, I., Steiner, M., Richi-Alberti, P., Acosta-Alfaro, A. V., Prats, I., & Muñoz-Fernández, S. (2025). Prevalence of psoriatic arthritis in patients with moderate-to-severe psoriasis in the era of biologics and small molecule therapies. Journal of Clinical Medicine, 14(23), 8359. https://doi.org/10.3390/jcm14238359
dc.identifier.doi10.3390/jcm14238359
dc.identifier.issn2077-0383
dc.identifier.urihttps://hdl.handle.net/11268/16834
dc.language.isoeng
dc.peerreviewedSi
dc.relation.publisherversionhttps://doi.org/10.3390/jcm14238359
dc.rightsAttribution 4.0 Internationalen
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subject.otherPrevalencia
dc.subject.otherPsoriasis
dc.subject.otherArtritis psoriática
dc.subject.sdgGoal 3: Ensure healthy lives and promote well-being for all at all ages
dc.subject.unescoInvestigación médica
dc.subject.unescoMedicina preventiva
dc.subject.unescoLucha contra las enfermedades
dc.titlePrevalence of Psoriatic Arthritis in Patients with Moderate-to-Severe Psoriasis in the Era of Biologics and Small Molecule Therapies.
dc.typejournal article
dc.type.hasVersionVoR
dspace.entity.typePublication
relation.isAuthorOfPublicationd2fd2866-7549-4771-ab4e-efc5d0c36e24
relation.isAuthorOfPublicatione63bfc36-22f0-41ab-baa8-6bedf9007186
relation.isAuthorOfPublicationd2fd2866-7549-4771-ab4e-efc5d0c36e24
relation.isAuthorOfPublicationaf8b4da6-c0e8-459a-8f7f-8b365df94d3b
relation.isAuthorOfPublicationaf8b4da6-c0e8-459a-8f7f-8b365df94d3b
relation.isAuthorOfPublication.latestForDiscoveryd2fd2866-7549-4771-ab4e-efc5d0c36e24

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Prevalencia APs en Psoriasis.pdf
Size:
695.19 KB
Format:
Adobe Portable Document Format
Download

Collections

Área de Ciencias de la Salud